Next Article in Journal
Drug Development for Pediatric Populations: Regulatory Aspects
Open AccessArticle

Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids

1
Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FIN- 00014, University of Helsinki, Finland
2
School of Pharmacy, Howard University, 2300 Fourth Street, NW, Washington, DC 20059, USA
3
Irma Lerma Rangel College of Pharmacy, Texas A&M Health Sciences Center, MSC 131, 1010 West Avenue B, Kingsville, TX 78363, USA
*
Author to whom correspondence should be addressed.
Pharmaceutics 2010, 2(4), 339-350; https://doi.org/10.3390/pharmaceutics2040339
Received: 21 September 2010 / Revised: 20 October 2010 / Accepted: 26 October 2010 / Published: 27 October 2010
Several biologically relevant phospholipids were assessed as potential carriers/additives for rapidly dissolving solid formulations of piroxicam (Biopharmaceutics Classification System Class II drug). On the basis of in vitro dissolution studies, dimyristoylphosphatidylglycerol (DMPG) was ranked as the first potent dissolution rate enhancer for the model drug. Subsequently, the solid dispersions of varying piroxicam/DMPG ratios were prepared and further investigated. Within the concentration range studied (6.4-16.7 wt %), the dissolution rate of piroxicam from the solid dispersions appeared to increase as a function of the carrier weight fraction, whereas the cumulative drug concentration was not significantly affected by piroxicam/DMPG ratio, presumably due to a unique phase behavior of the aqueous dispersions of this carrier phospholipid. Solid state analysis of DMPG-based formulations reveled that they are two-component systems, with a less thermodynamically stable form of piroxicam (Form II) being dispersed within the carrier. Finally, oral bioavailability of piroxicam from the DMPG-based formulations in rats was found to be superior to that of the control, as indicated by the bioavailability parameters, cmax and especially Tmax (53 µg/mL within 2 h vs. 39 µg/mL within 5.5 h, respectively). Hence, DMPG was regarded as the most promising carrier phospholipid for enhancing oral bioavailability of piroxicam and potentially other Class II drugs. View Full-Text
Keywords: poorly water soluble drugs; phospholipids; solid dispersions; dissolution; bioavailability poorly water soluble drugs; phospholipids; solid dispersions; dissolution; bioavailability
Show Figures

Figure 1

MDPI and ACS Style

Mirza, S.; Miroshnyk, I.; Habib, M.J.; Brausch, J.F.; Hussain, M.D. Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids. Pharmaceutics 2010, 2, 339-350. https://doi.org/10.3390/pharmaceutics2040339

AMA Style

Mirza S, Miroshnyk I, Habib MJ, Brausch JF, Hussain MD. Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids. Pharmaceutics. 2010; 2(4):339-350. https://doi.org/10.3390/pharmaceutics2040339

Chicago/Turabian Style

Mirza, Sabiruddin; Miroshnyk, Inna; Habib, Muhammad J.; Brausch, James F.; Hussain, Muhammad D. 2010. "Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids" Pharmaceutics 2, no. 4: 339-350. https://doi.org/10.3390/pharmaceutics2040339

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop